FDA Accepts Supplement Application for NUZYRA (Omadacycline Tosylate)
The FDA has accepted a supplemental application for NUZYRA, indicating ongoing development and potential label expansion.
Asset / Drug
Drug and asset intelligence for NUZYRA with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.